In conclusion, targeting HER2 is revealing a fine and increasingly more complex work concerning the growing knowledge of the topic, that determines a deeper understanding of molecular mechanisms underlying the variable expression of HER2 in different tumors and even in different cells of the same tumor, a knowledge that is at the same time necessary to develop more effective therapies for breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.